A groundbreaking discovery has shed light on a potential shield for liver health, especially for children at risk due to their mothers' dietary choices during pregnancy and breastfeeding. The stakes are high, as fatty liver disease can have a devastating impact on a child's future health.
New research from the University of Oklahoma suggests a way to lower this risk. The study focused on a naturally occurring compound called indole, produced by our gut's beneficial bacteria. When given to pregnant and nursing mice, their offspring showed significantly reduced rates of fatty liver disease as they aged.
This finding adds to the growing body of research aimed at preventing metabolic dysfunction-associated steatotic liver disease (MASLD), a condition affecting both adults and children, but often more aggressively in the latter.
"The prevalence of MASLD in children is concerning, with about 30% of obese children and 10% of non-obese children affected," said Jed Friedman, Ph.D., director of the OU Health Harold Hamm Diabetes Center. "The disease often goes unnoticed until a child exhibits liver-related symptoms, and the risk is heightened if the mother is obese or follows an unhealthy diet."
The study, led by Friedman and Karen Jonscher, Ph.D., set out to explore the role of the microbiome in fatty liver disease development. Female mice were fed a Western-style diet high in fat and sugar throughout pregnancy and lactation, with some also receiving indole.
"A poor maternal diet can significantly impact the infant's microbiome, potentially causing harm," Friedman explained. Indeed, the offspring born to mothers receiving indole exhibited multiple health benefits. They had healthier livers, managed weight gain better, maintained lower blood sugar levels, and developed smaller fat cells, even when exposed to an unhealthy diet later in life.
The researchers also observed the activation of a protective gut pathway involving the acyl hydrocarbon receptor (AHR). Additionally, the study found no increase in harmful long-chain ceramides in the liver, while beneficial very long-chain ceramides increased.
In a crucial experiment, gut bacteria from the protected offspring were transferred to mice that hadn't received indole. These mice also experienced less liver damage, further emphasizing the central protective role of the microbiome.
While the research was conducted on animals and cannot yet be directly applied to humans, it points to new strategies for early prevention of MASLD, which currently has no approved medications and relies solely on weight loss for treatment.
"Improving the mother's microbiome could be a powerful tool in preventing MASLD in children," Jonscher said. "It's a far more desirable approach than trying to reverse the disease once it's progressed."
This research opens up new avenues for exploration and offers a glimmer of hope in the fight against fatty liver disease in children.
